Overview
Offers new insight into strategies for development of antibody-based therapeutics
Discusses design of animal models in identifying potential risks to humans
Shows how the flow of information from later to earlier stages of development can facilitate selection of more effective novel and next-generation drug candidates
Access this book
Tax calculation will be finalised at checkout
Other ways to access
Table of contents (13 chapters)
-
Front Matter
Keywords
About this book
This, the second edition of Development of Antibody-Based Therapeutics: Translational Considerations, represents a comprehensive evaluation of progress in the field, which sits alongside the first edition to inform, in detail, professional and academic researchers, as well as graduate students.
Editors and Affiliations
About the editors
Mohammad A. Tabrizi, Ph.D. is a leader in translational sciences as related to development of antibody-based therapeutics. His product development experience spans many therapeutic areas including oncology and inflammatory disease, and his technical expertise includes preclinical pharmacology and safety, preclinical and clinical pharmacokinetics, pharmacodynamics, GLP-compliant bioanalytics, and clinical pharmacology of therapeutic monoclonal antibodies.
Following his postdoctoral training, Dr. Bornstein joined Amgen Fremont, Inc. (formerly Abgenix, Inc.) as a Staff Scientist in the Preclinical Oncology department. Dr. Bornstein has held roles of increasing responsibility at AstraZeneca, Pfizer, and Novartis, where he was a project team leader, lead biologist, and key contributor to scientific strategies for multiple oncology programs. Dr. Bornstein has authored numerous research papers, reviews, as well as book chapters, and is a co-inventor on multiple patents.
Scott L. Klakamp, Ph.D. is one of the leading scientists in utilizing Surface Plasmon Resonance (SPR) and KinExA® to measure the binding kinetics and equilibrium dissociation constants of human monoclonal antibody/antigen complexes. He was the founder of SKD Consulting LLC and acted as Principal Consultant at that company during the development of this title. Prior to SKD Consulting LLC, he was the Vice President of Chemistry and Biochemistry at BiOptix Inc., a company that provided the 404pi biosensor. Dr. Klakamp has also held positions of increasing responsibility in the areas of analytical and biophysical characterization at Chiron, Amgen/Abgenix, AstraZeneca/MedImmune, and Takeda Pharmaceuticals. Dr. Klakamp has been an author on over 30 research and review papers, book chapters, and patents. He has also been an invited speaker at numerous international and national meetings. Dr. Klakamp received his B.A. in Chemistry from Houghton College and his PhD in Chemistry at the Pennsylvania State University. From 1990 to 1993, he completed a postdoctoral fellowship (funded by a National Research Service Award from the National Institutes of Health) at the California Institute of Technology in bioinorganic chemistry.Bibliographic Information
Book Title: Development of Antibody-Based Therapeutics
Book Subtitle: Translational Considerations & Challenges
Editors: Mohammad A. Tabrizi, Gadi G. Bornstein, Scott L. Klakamp
DOI: https://doi.org/10.1007/978-981-13-0496-5
Publisher: Adis Singapore
eBook Packages: Medicine, Medicine (R0)
Copyright Information: Springer Nature Singapore Pte Ltd. 2018
Hardcover ISBN: 978-981-13-0495-8Published: 12 November 2018
Softcover ISBN: 978-981-13-4432-9Published: 30 January 2019
eBook ISBN: 978-981-13-0496-5Published: 11 September 2018
Edition Number: 2
Number of Pages: VIII, 248
Number of Illustrations: 19 b/w illustrations, 87 illustrations in colour
Topics: Pharmacy, Pharmacology/Toxicology, Biochemistry, general